Patient and product factors affecting platelet transfusion results

BACKGROUND: Providing patients with platelet (PLT) transfusions requires important logistic resources and represents a considerable cost factor. Optimizing PLT transfusions is in the interest of not only patient safety but also economic importance. Only few studies have evaluated factors associated with transfusion results.

[1]  J. Mckitrick.  Triggers , 2018, Encyclopedia of Database Systems.

[2]  R. Brand,et al.  A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. , 2006, Blood.

[3]  Edward J. Lee,et al.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. , 2005, Blood.

[4]  B. Giraudeau,et al.  The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. , 2005, Blood.

[5]  P. Rebulla,et al.  Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. , 2004, The Cochrane database of systematic reviews.

[6]  P. Rebulla,et al.  Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers , 2004, Transfusion.

[7]  J. AuBuchon,et al.  Preliminary validation of a new standard of efficacy for stored platelets , 2004, Transfusion.

[8]  Guidelines for the use of platelet transfusions , 2003, British journal of haematology.

[9]  J M Rainey,et al.  Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Bins,et al.  Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study , 2000, Transfusion.

[11]  J. Herman,et al.  Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double‐blind trial , 1999, Transfusion.

[12]  T. Barbui,et al.  The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1997, The New England journal of medicine.

[13]  Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. , 1997, The New England journal of medicine.

[14]  R. Hawker,et al.  Paired in vivo and in vitro comparison of apheresis and “recovered” platelet concentrates stored for 5 days , 1994, Journal of clinical apheresis.